Verrica Pharmaceuticals Inc. (NASDAQ: VRCA)

Verrica Pharmaceuticals Inc. is a therapeutics company focused on developing and commercializing medications for dermatologic diseases. The firm's lead product YCANTH is a topical treatment for molluscum contagiosum. The company also advances product candidates for common warts and basal cell carcinoma. It operates in the specialty pharmaceutical sector targeting skin conditions.

Verrica generates revenue primarily from sales of its approved product YCANTH in the United States. The company also receives milestone and royalty payments from collaboration partners such as Torii Pharmaceutical for development and commercialization rights in Japan. Additionally it may earn future revenue from licensing agreements and potential product sales once its pipeline candidates receive regulatory approval.

Verrica holds a distinct position as the first company to secure FDA approval for a prescription therapy for molluscum contagiosum. Its product YCANTH benefits from a proprietary formulation of cantharidin and a single use applicator that offers consistent dosing and ease of administration. Competitors include over the counter remedies and off label procedures such as cryotherapy curettage and laser surgery as well as the newly approved berdazimer gel for molluscum. The company's competitive advantages stem from its regulatory exclusivity patent protection and specialized sales force targeting dermatology and pediatric providers.

Verrica sells YCANTH to dermatologists pediatricians pediatric dermatologists and other primary care health care providers who administer the drug in office settings. The product is accessed through wholesale distribution partners and white bag services from specialty pharmacies. While the filing does not disclose specific customer names the typical clients are medical practices and clinics that treat patients with molluscum warts and skin lesions.